Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: allen menglin chen who wrote (303)	5/8/2000 8:02:00 PM
From: gao seng	Read Replies (1) \| Respond to of 746

"We are not in the business of patenting genes," he said. "We are in the business of proving information and analytical tools for genetic research." marketwatch.newsalert.com I find it fishy that the headline says they have completed the first annotation of the human genome. That is not the same as complete a complete annotation. I don't know, but certainly somewhere someone has annotated it somewhat? CRA is into proteomics. GNSL is a provider of genomic information, the same as incy and doubletwist. I do not consider doubletwist to be a threat to CRA, but possibly a future partner. But proteomics is where the money is. lol, that and it really isn't that complicated.